BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7252329)

  • 1. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
    Webb J; Vitolo ML
    Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
    [No Abstract]   [Full Text] [Related]  

  • 4. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
    Johnson DK; Pippard MJ; Murphy TB; Rose NJ
    J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
    Cikrt M; Ponka P; Necas E; Neuwirt J
    Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture.
    Richardson D; Baker E; Ponka P; Wilairat P; Vitolo ML; Webb J
    Birth Defects Orig Artic Ser; 1988; 23(5B):81-8. PubMed ID: 3390577
    [No Abstract]   [Full Text] [Related]  

  • 7. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR; Ponka P
    J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
    Bláha K; Cikrt M; Nerudová J; Ponka HF
    Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
    Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
    Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.
    Richardson DR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2061-3. PubMed ID: 9303419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate.
    Santos NC; Castilho RF; Meinicke AR; Hermes-Lima M
    Eur J Pharmacol; 2001 Sep; 428(1):37-44. PubMed ID: 11779035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
    Vitolo ML; Clare BW; Hefter GT; Webb J
    Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
    Buss JL; Arduini E; Shephard KC; Ponka P
    Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC study on stability of pyridoxal isonicotinoyl hydrazone.
    Kovaríková P; Mokrý M; Klimes J; Vávrová K
    J Pharm Biomed Anal; 2006 Jan; 40(1):105-12. PubMed ID: 16061341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
    Hershko C; Grady RW; Link G
    Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
    Richardson DR; Tran EH; Ponka P
    Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
    Baker E; Vitolo ML; Webb J
    Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridoxal Isonicotinoyl Hydrazone Improves Neurological Recovery by Attenuating Ferroptosis and Inflammation in Cerebral Hemorrhagic Mice.
    Zhang H; Wen M; Chen J; Yao C; Lin X; Lin Z; Ru J; Zhuge Q; Yang S
    Biomed Res Int; 2021; 2021():9916328. PubMed ID: 34541001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
    Ponka P; Richardson DR; Edward JT; Chubb FL
    Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
    Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
    Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.